BioXcel Therapeutics, Inc. Common Stock
BTAIBioXcel Therapeutics, Inc. (BTAI) is a biotechnology company focused on the development and commercialization of artificial intelligence-driven therapies for neuroscience and immuno-oncology indications. The company utilizes its proprietary platform to identify and develop innovative drug candidates, aiming to address unmet medical needs in areas such as acute neuropsychiatric disorders and cancer.
Company News
BioXcel Therapeutics will ring the Nasdaq Closing Bell to celebrate its breakthrough progress in treating agitation associated with bipolar disorders and schizophrenia, highlighting the successful completion of its SERENITY At-Home pivotal trial.
BioXcel Therapeutics announced it has regained compliance with Nasdaq's market value listing requirements after previously being notified of non-compliance in March 2025.
BioXcel Therapeutics reported positive results from its SERENITY At-Home Phase 3 trial for BXCL501, demonstrating safety and potential for at-home treatment of agitation in bipolar and schizophrenia patients. The company plans to submit a supplemental New Drug Application (sNDA) in Q1 2026.
BioXcel Therapeutics will host an investor call on August 27, 2025, to review topline data from its SERENITY At-Home Phase 3 trial evaluating BXCL501's safety for treating agitation in bipolar disorders and schizophrenia patients.
BioXcel Therapeutics received positive FDA feedback for its supplemental New Drug Application (sNDA) to expand IGALMI's label for at-home treatment of agitation in bipolar disorders and schizophrenia, with sNDA submission expected in Q1 2026.
